Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Conmed (CNMD) Non-Current Debt (2016 - 2025)

Historic Non-Current Debt for Conmed (CNMD) over the last 16 years, with Q4 2025 value amounting to $834.2 million.

  • Conmed's Non-Current Debt fell 782.66% to $834.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $834.2 million, marking a year-over-year decrease of 782.66%. This contributed to the annual value of $834.2 million for FY2025, which is 782.66% down from last year.
  • Per Conmed's latest filing, its Non-Current Debt stood at $834.2 million for Q4 2025, which was down 782.66% from $853.0 million recorded in Q3 2025.
  • Conmed's Non-Current Debt's 5-year high stood at $1.0 billion during Q3 2022, with a 5-year trough of $672.4 million in Q4 2021.
  • Moreover, its 5-year median value for Non-Current Debt was $922.6 million (2024), whereas its average is $882.9 million.
  • Its Non-Current Debt has fluctuated over the past 5 years, first crashed by 1045.22% in 2021, then skyrocketed by 4736.05% in 2022.
  • Conmed's Non-Current Debt (Quarter) stood at $672.4 million in 2021, then skyrocketed by 46.5% to $985.1 million in 2022, then dropped by 1.21% to $973.1 million in 2023, then fell by 7.0% to $905.1 million in 2024, then dropped by 7.83% to $834.2 million in 2025.
  • Its last three reported values are $834.2 million in Q4 2025, $853.0 million for Q3 2025, and $881.1 million during Q2 2025.